Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics by Tran, Trung D et al.
© 2007 Dove Medical Press Limited.   All rights reserved
International Journal of Nanomedicine 2007:2(4) 515–526 515
REVIEW
Clinical applications of perﬂ  uorocarbon nanoparticles 
for molecular imaging and targeted therapeutics
Trung D Tran1
Shelton D Caruthers1,2
Michael Hughes1
John N Marsh1
Tillmann Cyrus1
Patrick M Winter1
Anne M Neubauer1
Samuel A Wickline1
Gregory M Lanza1
1Division of Cardiology, Washington 
University Medical School, 660 South 
Euclid Blvd, St Louis, Missouri, USA; 
2Philips Medical Systems, Cleveland, 
Ohio, USA
Correspondence: Gregory M Lanza
Associate Professor of Medicine and 
Bioengineering, Division of Cardiology, 
Washington University Medical School, 
660 S. Euclid Ave, Campus Box 8086, Saint 
Louis, MO 63110, USA
Tel +1 314 454 8813
Fax +1 314 454 5265
Email greg@cvu.wustl.edu
Abstract: Molecular imaging is a novel tool that has allowed non-invasive diagnostic imaging 
to transition from gross anatomical description to identiﬁ  cation of speciﬁ  c tissue epitopes and 
observation of biological processes at the cellular level. This technique has been conﬁ  ned to 
the ﬁ  eld of nuclear imaging; however, recent advances in nanotechnology have extended this 
research to include ultrasound (US) and magnetic resonance (MR) imaging. The exploitation 
of nanotechnology for MR and US molecular imaging has generated several candidate contrast 
agents. One multimodality platform, targeted perﬂ  uorocarbon (PFC) nanoparticles, is useful for 
noninvasive detection with US and MR, targeted drug delivery, and quantiﬁ  cation.
Keywords: nanoparticles, perﬂ  uorocarbon, molecular imaging, ultrasound, magnetic resonance 
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Introduction
Recent advances in genomics, proteomics and molecular biology have created an 
unprecedented opportunity to identify clinical pathology in their “pre-disease” states. 
Unfortunately, detection of small aggregates of dysplastic cells and their biochemi-
cal signatures are beyond the resolution and sensitivity of conventional acoustic and 
magnetic resonance imaging techniques. Recognition of these molecular epitopes 
requires target-speciﬁ  c probes, a robust signal ampliﬁ  cation strategy and a sensitive 
high-resolution imaging modality.
Numerous nano- or micro-particle systems are in development for targeted diagnos-
tic imaging and drug delivery, which have been recently reviewed (Cyrus et al in press). 
The perﬂ  uorocarbon (PFC) nanoparticle is a unique platform technology, which may 
be applied to clinically relevant modalities and illustrates many of the key principles 
found in other agents. Ligand-directed, lipid-encapsulated, liquid PFC nanoparticles 
(250 nm nominal diameter) have inherent physicochemical properties, which provide 
acoustic contrast when the agent is bound in aggregate to a surface. High surface area of 
the nanoparticle accommodates 50 to 500 homing ligands, which imparts high avidity 
and gives the agent a robust “stick and stay” quality (see Figure 1). Surface incorpo-
ration of large payloads of lipid-gadolinium chelate conjugates further extends the 
utility of the agent to detect sparse concentrations of cell surface biochemical markers 
with MRI (Lanza, Lorenz et al 1998). Moreover, the high ﬂ  uorine signal from the 
nanoparticle core allows noninvasive quantiﬁ  cation of ligand-bound particles, which 
will permit clinicians to conﬁ  rm tissue concentrations of drugs when functionality of 
the nanoparticles is extended to include targeted therapy (see Figure 2).
The deﬁ  nition of nanoparticle is varied based on the perspective and historical time-
frame. In the materials section of the NIH and NSF, the size of nanoparticles deﬁ  ned 
by a change in the properties of structures, particularly with respect to their quantum 
features for optical imaging. The NCI and NHLBI typically refer to nanoparticles in 
their RFAs for biomedical applications at 300 nm and the Europeans use a 500 nm International Journal of Nanomedicine 2007:2(4) 516
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cut-off. In biomedical applications, the surface to volume 
ratio and the pharmacokinetics and biodistribution features 
of nanoparticles are the important qualities. Although 
the majority of nanoparticles are synthetic using natural 
products or polymers, there are contingents of scientists 
that encouraging the NIH to include engineered viruses as 
nanoparticles! Thus in reality, the deﬁ  nition of nanoparticle 
in the biological sciences is dynamic, referring to particles 
generally less than 500 nm and typically, though not exclu-
sively, chemically synthesized or fabricated.
Figure 1 Scanning electron micrographs (x30 000) of control ﬁ  brin clot (A) and ﬁ  brin-targeted paramagnetic nanoparticles bound to the clot surface (B). Arrows indicate 
(A) ﬁ  brin ﬁ  bril; (B) ﬁ  brin-speciﬁ  c nanoparticles-bound to ﬁ  brin epitopes. Copyright © 2001. Reprinted with permission from Flacke S, Fischer S, et al. 2001. Novel MRIM
contrast agent for molecular imaging of ﬁ  brin: implications for detecting vulnerable plaques. Circulation, 104:1280–5. 
Figure 2 Paradigm for targeted liquid perﬂ  uorocarbon-based nanoparticle contrast agents. This example has a payload of Gd3+ chelates and monoclonal antibodies. This 
platform is extremely versatile and applicable to almost any imaging modalities and capable of carrying other payloads such as drugs or genes.
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Targeted versus non-targeted 
contrast agents
Localization of non-targeted contrast agents depends greatly 
upon the body’s innate system for clearance of foreign par-
ticles, ie, the reticuloendothelial system (RES). Macrophages 
of the RES are responsible for the removal of these contrast 
agents from the circulation, which occurs in a size-dependent 
fashion from the lung, spleen, liver and bone marrow. Fur-
thermore, phagocytosis and accumulation within speciﬁ  c 
sites can be enhanced by opsonization (ie, biologic tagging) 
with blood proteins such as immunoglobins, complement 
proteins or nonimmune serum factors. In general, liver 
sequestration appears to be complement mediated, while 
the spleen removes foreign particulate matter via antibody 
Fc receptors (Moghimi and Patel 1989). This process of 
nonspeciﬁ  c and nondirected uptake of particles is generally 
referred to as “passive targeting”.
Ligand-directed (“targeted”) contrast agents are designed 
to identify speciﬁ  c pathological tissue that otherwise might 
be difﬁ  cult to distinguish from surrounding normal tissue. A 
wide variety of ligands can be utilized including monoclonal 
antibodies and fragments, peptides, polysaccharides, aptamers 
and drugs. These ligands may be attached covalently (ie, direct 
conjugation) or non-convalently (ie, indirect conjugation) to 
the contrast agent. Further surface modiﬁ  cation, such as the 
incorporation of polyethylene glycol, are used to delay or 
avoid rapid systemic removal of the agents and allow ligand-
to-target binding to occur. To demonstrate the effectiveness 
of this concept of targeting contrast agents, we need only 
look at the application of paramagnetic MRI contrast agents. 
Paramagnetic agents only inﬂ  uence protons in their immedi-
ate vicinity and removal of these contrast agents by the RES 
during passive targeting may decrease their effectiveness via 
two mechanisms: (1) accumulation of contrast agent in speciﬁ  c 
organs that are distal to region of interest, and (2) endocytosis 
further decreases their exposure to free water protons. By 
targeting the contrast agent, the paramagnetic ions can be 
brought in close proximity to the region of interest with sig-
niﬁ  cant accumulation to overcome the partial dilution effect 
that plagues some MR contrast agents. Its efﬁ  cacy is further 
enhanced with some targeting platforms by delivering multiple 
contrast ions per particle (Lanza, Lorenz et al 1998).
Basic principles of ultrasound contrast 
agents
Commercially available ultrasound contrast agents are based 
on gas-ﬁ  lled encapsulated microbubbles (~2.5–5 microns) that 
transiently enhance the blood pool signal, which is otherwise 
weakly echogenic. When insoniﬁ  ed by an ultrasound wave, 
microbubbles improve gray scale images and Doppler signal 
via two distinct mechanisms (Dalla Palma and Bertolotto 
1999; McCulloch et al 2000; Correas et al 2001). First, at 
lower acoustic power, microbubbles are highly efﬁ  cient scat-
ters due to their large differences in acoustic impedance (Z) 
compared with surrounding tissue or blood. With increasing 
acoustic energies, microbubbles begin non-linear oscilla-
tions and emit harmonics of the fundamental (incidence) 
frequencies; thus behaving as a source of sound, rather than 
as a passive reﬂ  ector. Biological tissue does not display this 
degree of harmonic generation, thus the contrast generated 
signal can be exploited to preferentially image microbubbles 
and improve signal-to-noise ratios. To emphasize these 
strong echogenic properties, it has been shown that even one 
microbubble can be detected with medical ultrasound systems 
(Klibanov et al 2004). Interestingly, destruction and cavitation 
of microbubbles by ultrasound waves have been suggested as 
a means to facilitate drug delivery by “sonoporating” mem-
branes and allowing drugs and gene therapy to enter the cell 
(Shohet et al 2000; Blomley et al 2001). However, the long 
term effects on cell viability have yet to be assessed. When 
this process occurs in capillary beds, permeability increases 
allowing a subset of particles access to surrounding tissue for 
further drug deposition et al 1998).
The wide use of microbubbles in everyday clinical appli-
cations highlight its effectiveness as a blood pool agent. For 
example, microbubbles enhance the blood-tissue boundary 
of the left ventricular cavity allowing for better diagnostic 
yield in resting as well as stress echocardiograms (Cheng 
et al 1998). Improved Doppler signals are beneﬁ  cial in the 
diagnosis of valvular stenosis and regurgitation (Terasawa 
et al 1993). Additionally, microbubbles are removed from cir-
culation via the RES and accumulate in the liver and spleen, 
ie, passive targeting. This mechanism can be employed for 
the detection of focal liver lesions and malignancies (Harvey 
et al 2000; Blomley et al 2001). For use as targeted contrast 
agents, microbubbles have been conjugated with ligands for a 
variety of vascular biomarkers including integrins expressed 
during angiogenesis, the glycoprotein IIb/IIIa receptor on 
activated platelets in clots and L-selectin for the selective 
enhancement of peripheral lymph nodes in vivo (Schumann 
et al 2002; Leong-Poi et al 2003; Hauff et al 2004). One 
disadvantage to the targeting of microbubbles is the “tether-
ing” of these particles to a surface. This interaction with a 
solid structure limits the ability of insoniﬁ  ed microbubbles 
to oscillate and dampens their echogenicity.International Journal of Nanomedicine 2007:2(4) 518
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As mentioned previously, we have developed a novel 
multidimensional targeted nanoparticle platform that is a 
ligand-targeted, lipid encapsulated, nongaseous perﬂ  uo-
rocarbon emulsion. It is robustly stable to handling, pres-
sure, atmospheric exposure, heat and shear forces. Unlike 
microbubble formulations that are naturally echogenic, these 
nanoparticles have poor inherent acoustic reﬂ  ectivity and 
have been shown to exhibit backscattering levels 30 dB below 
that of whole blood (Hughes et al 2005). However, when 
collective deposition occurs on the surfaces of tissues or a 
cell in a layering effect, these particles create a local acoustic 
impedance mismatch that produces a strong ultrasound sig-
nal without a concomitant increase in the background level 
(Lanza, Trousil et al 1998). The echogenicity of nanopar-
ticles does not depend upon the generation of harmonics and 
therefore is not affected by binding of nanoparticles with 
molecular epitopes. Due to their small size and inherent in 
vivo stability, perﬂ  uorocarbon nanoparticle emulsions have 
a long circulatory half-life compared to microbubble contrast 
agents. This is accomplished without modiﬁ  cation of their 
outer lipid surfaces with polyethylene glycol or incorporation 
of polymerized lipids, which can detract from the targeting 
efﬁ  cacy. Data suggest that the PFC nanoparticles persist 
when bound to tissue for hours and possibly days. Addi-
tionally, nongaseous nanoparticles do not easily deform or 
cavitate with ultrasound imaging.
Basic principles of MR contrast 
agents
In addition to acoustic imaging, this nanoparticle platform 
has been coupled to paramagnetic ions for MR imaging. As 
a dual-modality contrast agent, the strengths of ultrasound 
imaging, ie, ﬂ  exibility, portability and ease of use are com-
bined with the high spatial resolution of MR imaging. To 
understand how nanoparticles can be employed as an MR 
contrast agent, an understanding of the NMR phenomenon 
is crucial. The nuclei of elements such as hydrogen (1H) or 
ﬂ  uorine (19F), when exposed to a strong magnetic ﬁ  eld will 
change from their random orientation to adopt either a paral-
lel or anti-parallel alignment. Absorption of radiofrequency 
(RF) energy at a characteristic resonance frequency excites 
nuclei into a higher energy state. Upon termination of the 
RF excitation, nuclei return to the previous lower energy 
state in an exponential fashion with a characteristic rate time 
constant known as T1 (ie, spin-lattice or longitudinal relax-
ation). This process of excitation and relaxation results in a 
changing magnetic ﬁ  eld that is detectable with an external RF 
antenna. This detected signal strength is diminished due to 
dephasing, which is a process of nuclei to nuclei interactions 
(ie, spin-spin or transverse relaxation) characterized by the 
time constant T2. T1 and T2 relaxation times, as well as the 
density of the nuclei of interest, determine signal intensity 
of various types of tissue in MR imaging.
MR contrast agents work by shortening T1 and T2. The 
most commonly used non-targeted MR contrast agents uti-
lize paramagnetic ions (eg, gadolinium chelates) and they 
predominantly shorten T1 relaxation resulting in a “bright” 
signal on T1 weighted images. T1 agents chieﬂ  y inﬂ  uence 
protons proximate to themselves and are highly dependent on 
local water ﬂ  ux (Lanza et al 2004). Superparamagnetic and 
ferromagnetic compounds have a high magnetic susceptibil-
ity and produce local disturbances in the ﬁ  eld (Nelson and 
Runge 1995). These disturbances induce signal dephasing 
in tissue and result in loss of signal through apparent T2 
decay (ie, T2*). Contrary to T1 contrast agents, superpara-
magnetic agents have a net effect far beyond their immediate 
vicinity.
For use as a T1 weighted paramagnetic contrast agent, PFC 
nanoparticles can be functionalized by surface incorporation 
with homing ligands and typically 100,000 gadolinium che-
lates (Gd3+) per particle (Flacke et al 2001). In addition, all of 
the paramagnetic ions are present in the outer surface where 
they optimally inﬂ  uence the local water for maximum effect 
on T1 relaxation (Winter, Caruthers et al 2003). The result is 
PFC nanoparticles that are capable of overcoming the diluting 
partial volume effects that plague most MR contrast agents 
(Gupta and Weissleder 1996). To illustrate the potency of this 
contrast agent platform, we need only examine its relaxivity. 
The efﬁ  ciency of an MR contrast agent can be described by 
its relaxivity (mM–1sec–1), which is simply calculated as the 
change in relaxation rate (1/T1 or T2) divided by the concen-
tration of the contrast agent. The relaxivity of Gd3+ in saline 
(4.5 mM–1sec–1) (Stanisz and Henkelman 2000) is lower when 
compared to Gd3+ bound to the surface of a PFC nanoparticles 
(33.7 mM–1sec–1) (Winter, Caruthers et al 2003) at 1.5T. Since 
each nanoparticle bears high payloads of Gd ions, the overall 
relaxivity of the construct, also referred to as the particle-based 
relaxivity, has been measured at over 2,000,000 mM–1sec–1 
(Winter, Caruthers et al 2003). This allows for detection and 
quantiﬁ  cation of tissue biomarkers at low nanomolar concen-
trations (Morawski et al 2004).
PFC nanoparticles for ﬂ  uorine (19F) 
MR spectroscopy and imaging
The intensity of an MR signal is directly proportional to 
the gyromagnetic ratio (γ) and density (number of nuclei International Journal of Nanomedicine 2007:2(4) 519
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in the volume of interest) (Bushong 2003). Though there 
are many medically relevant nuclei, the 1H proton is the 
most commonly imaged nuclei in clinical practice because 
of its high gyromagentic ratio, high natural abundance and 
high concentrations in biological tissue (see Table 1). Fluo-
rine-19, whose gyromagnetic ratio is close to 1H and has 
a natural abundance of virtually 100%, is a theoretically 
attractive nucleus for MR imaging (Longmaid et al 1985). 
Its sensitivity is 83% when compared to 1H at a constant ﬁ  eld 
strength and with equivalent number of nuclei. In biological 
tissue, low 19F concentrations (in the range of micromoles) 
makes MR imaging ineffective without 19F rich contrast 
agents (McFarland et al 1985). PFC nanoparticles are 98% 
perﬂ  uorocarbon by volume, which equates for perﬂ  uorooc-
tylbromide (1.98 g/ml, 498 daltons) to approximately 100M 
concentration of ﬂ  uorine within a nanoparticle. The paucity 
of endogenous ﬂ  uorine in biological tissue allows the use of 
exogenous PFC nanoparticles as an effective 19F MR con-
trast agent without interference from signiﬁ  cant background 
signal. When combined with local drug delivery, detection 
of the 19F signal serves as a highly speciﬁ  c marker for the 
presence of nanoparticles that would permit quantitative 
assessment of drug dosing.
19F has seven outer-shell electrons rather than a single 
electron as is the case with hydrogen; as a result, the range 
and sensitivity of chemical shifts to the details of the local 
environment are much higher for ﬂ  uorine than hydrogen. 
Distinct spectra from different perﬂ  uorocarbon species can 
be obtained and utilized for simultaneously distinguishing 
multiple biochemical markers via MR spectroscopy or imag-
ing (Caruthers et al 2006).
For use as a clinically applicable contrast agent, the 
biocompatibility of PFC nanoparticles must be reviewed. 
Liquid PFC were previously developed for use as a blood 
substitute (Sloviter and Mukherji 1983) and no toxicity, car-
cinogenicity, mutagenicity or teratogenic effects have been 
reported for pure ﬂ  uorocarbons within the 460 to 520 MW 
range. PFC’s are inert biologically and removed through the 
RES and excreted primarily through the lungs and in small 
amounts through the skin (Joseph et al 1985). Tissue half-
life ranges from 4 days for perﬂ  uorooctylbromide up to 65 
days for perﬂ  uorotripropylamine. The prolonged systemic 
half-life of PFC nanoparticles in conjunction with the local 
concentrating effect produced by ligand-directed binding, 
permit  19F spectroscopy and imaging studies at clinically 
relevant magnetic ﬁ  eld strengths (Yu et al 2000).
Fibrin-imaging for detection
of unstable plaque and thrombus
Of the over 720,000 cardiac related deaths per year in the 
United States, roughly 63% are classiﬁ  ed as sudden car-
diac death (SCD) (Zheng et al 2001). Unfortunately for 
many patients, this is the ﬁ  rst and only symptom of their 
atherosclerotic heart disease (ASHD) (Kuller et al 1966). 
Atherosclerosis begins as a fatty streak and without proper 
treatment, it can progress to a vulnerable plaque character-
ized by a large lipid core, thin ﬁ  brous cap and macrophage 
inﬁ  ltrates (Naghavi 2003). These vulnerable plaques are 
prone to rupture which can lead to thrombosis, vascular 
occlusion and subsequent myocardial infarction (Davies and 
Thomas 1985) or stroke. Routine angiography is the most 
common method of diagnosing ASHD with identiﬁ  cation 
of high grade lesions (70% stenosis) being referred for 
immediate therapeutic intervention. Ironically, most ruptured 
plaques originate from coronary lesions classiﬁ  ed as “non-
stenotic” (Naghavi et al 2003). Even nuclear and US based 
stress test are only designed to detect ﬂ  ow limiting lesions. 
Because the most common source of thromboembolisms 
come from atherosclerotic plaques with 50%–60% stenosis 
(Ambrose et al 1988), diagnosis by traditional techniques 
remains elusive. In addition, there appears to be a “window 
of opportunity” that exists between the detection of a vulner-
able or ruptured plaque and acute myocardial infarction (a 
few days to months) (Ojio et al 2000) in which intervention 
could prove to be beneﬁ  cial.
Acoustic enhancement of thrombi using ﬁ  brin targeted 
nanoparticles was ﬁ  rst demonstrated in vitro as well as in 
vivo in a canine model at frequencies typically used in clini-
cal transcutaneous scanning (Lanza et al 1996). Detection of 
thrombi was later expanded to MRI in a study by Flacke et al 
(2001). Fibrin clots were targeted in vitro with paramagnetic 
nanoparticles and imaged using typical “low” resolution T1 
proton imaging protocols (gradient and spin echo) at 1.5T. Low 
resolution images show enhancement of MR signal by the PFC 
nanoparticles and appear to completely ﬁ  ll the clot volume (see 
Figure 3). However, at higher in-plane resolution, the same clot 
Table 1 MRI properties of clinically important nuclei
Nuclei Gyromagnetic Spin  Natural  Relative
 ratio  quantum  abundance  sensitivity
 (MHz/T)  number  (%)
1H 42.6  1/2  99  1.0
13C 10.7  1/2 1.1  0.016
17O 5.8  5/2 0.1  0.029
19F 40.0  ½ 100  0.83
23Na 11.3  3/2  100  0.093
31P 17.2  1/2  100  0.07International Journal of Nanomedicine 2007:2(4) 520
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reveals that the nanoparticles were bound only at the surface and 
were excluded from penetration into the dense ﬁ  brin matrix (see 
Figure 1). In the same study, in vivo MR images were obtained 
of ﬁ  brin clots in the external jugular vein of dogs. Enhancement 
with ﬁ  brin targeted PFC nanoparticles produced high signal 
intensity in treated clots (1780 ± 327), whereas the control clot 
had a signal intensity (815 ± 41) similar to that of the adjacent 
muscle (768 ± 47). This method was extended to the detection 
of ruptured plaque in human carotid artery endarterectomy 
specimens resected from a symptomatic patient (see Figure 4). 
Fibrin deposition was localized to the shoulders of the ruptured 
plaque in the targeted vessel but this was not appreciated in the 
control. Further investigation in the molecular imaging of ﬁ  brin in 
ruptured plaque may someday detect this silent pathology sooner 
in order to preempt stroke or myocardial infarction.
The high ﬂ  uorine content of ﬁ  brin-targeted PFC nanopar-
ticles as well as the lack of background signal were exploited 
for  19F MR imaging and spectroscopy. In a recent study, 
Morawski et al (2004) describe several methods for quantifying 
the number of nanoparticles bound to a ﬁ  brin clot using the 
19F signal. First, ﬁ  brin-targeted paramagnetic perﬂ  uoro-crown-
ether nanoparticles and trichloroﬂ  uoromethane 19F spectra 
were obtained (Figure 5a). The relative crown ether signal 
intensity (normalized to the external trichloroﬂ  uoromethane 
reference) from known emulsion volumes provided a calibra-
tion curve for nanoparticle quantiﬁ  cation (Figure 5b). The PFC 
(crown ether) nanoparticles were then mixed in titrated ratios 
with ﬁ  brin-targeted nanoparticles containing safﬂ  ower oil and 
bound to plasma clots in vitro. As the competing amount of 
safﬂ  ower agent was increased, there was a linear decrease in 
19F signal. Bound NP was calculated from the 19F signal and the 
calibration curve described above and compared with the mass 
of Gd3+ tracer as determined by neutron activitation analysis. 
As expected, there was excellent agreement between measured 
Gd3+ mass and number of bound nanoparticles (calculated from 
the 19F signal) (see Figure 5c).
In addition, clots were treated with fibrin targeted 
nanoparticles with two distinct perﬂ  uorocarbon cores, crown 
ether and PFOB (Morawski et al 2004). They both exhibited 
Control Targeted
Calcium
α− Fibrin NP
Lumen
Plasma
Figure 4 Color enhanced magnetic resonance imaging of ﬁ  brin-targeted and con-
trol carotid endarterectomy speciments revealing contrast enhancement (white) of 
a small ﬁ  brin deposit on a symptomatic ruptured plaque. Calcium deposit (black). 
3D, fat-suppressed, T1-weighted fast gradient echo. Copyright © 2001. Reprinted 
with permission from Flacke S, Fischer S, et al. 2001. Novel MRI contrast agent for 
molecular imaging of ﬁ  brin: implications for detecting vulnerable plaques. Circulation, 
104:1280–5. 
Figure 3 (Left) Low-resolution images (3D gradient and spin echo) of control and (Middle) ﬁ  brin-targeted clot with paramagnetic nanoparticles presenting a homogenous, 
T1-weighted enhancement. (Right) High resolution scans of ﬁ  brin clots (3D T1-weighted gradient recalled echo sequence), revealing that image B results from a thin layer 
of paramagnetic nanoparticles along the surface. Copyright © 2001. Reprinted with permission from Flacke S, Fischer S, et al. 2001. Novel MRI contrast agent for molecular 
imaging of ﬁ  brin: implications for detecting vulnerable plaques. Circulation, 104:1280–5.
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two distinct 19F spectra at 4.7T and the binding of each respec-
tive nanoparticles was highly related to the ratio of PFOB and 
crown ether emulsion applied. These ﬁ  ndings demonstrate 
the possibility of simultaneous imaging and quantifying two 
separate nanoparticles and hence two distinct biomarkers 
(Caruthers et al 2006).
The clinical exercise of these techniques was applied to 
the analysis of human carotid endarterectomy samples (see 
Figure 6). An optical image of the carotid revealed extensive 
plaques, wall thickening and luminal irregularities. Multi-slice 
1H images showed high levels of signal enhancement along 
the luminal surface due to binding of targeted paramagnetic 
nanoparticles to ﬁ  brin deposits (not shown in Figure 6). 19F 
projection images of the artery, taken in approximately 5 
min, showed an asymmetric distribution of ﬁ  brin-targeted 
nanoparticles around the vessel wall corroborating the signal 
enhancement observed with 1H MRI. Concomitant visualiza-
tion of 1H and 19F images would permit the visualization of 
anatomical and pathological information in a single image. 
In theory, atherosclerotic plaque burden could be visualized 
with paramagnetic PFC contrast enhanced 1H images while 
19F could locally identify plaques with high levels of ﬁ  brin 
and thus prone to rupture. This simultaneous information 
could improve treatment strategies.
Detection of angiogenesis
and vascular injury
As described previously, ligand-directed PFC nanoparticles 
are well suited to detect very sparse biomarkers, such as inte-
grins involved in the process of angiogenesis. Angiogenesis 
is a critical component in wound healing, inﬂ  ammation and 
development; but also contributes to the pathology of many 
disease processes such as diabetic retinopathy, rheumatoid 
arthritis, cancer and atherosclerosis. The process of angio-
genesis depends upon the adhesion interactions of vascular 
cells and the integrin ανβ3 has been identiﬁ  ed as playing a 
vital role in angiogenic vascular tissue. The function of ανβ3 
includes smooth muscle cell (SMC) migration and prolifera-
tion, vascular cell apoptosis, and vascular remodeling (Sajid 
and Stouffer 2002) and it is expressed on the luminal surface 
of activated endothelial cells but not on mature quiescent 
cells. These ﬁ  ndings support that the role of ανβ3 in patho-
logical conditions characterized by neovascularization may 
be an important diagnostic and therapeutic target. In fact, the 
use of a monoclonal antibody against ανβ3 has demonstrated 
inhibition of angiogenesis without affecting mature vessels 
(Brooks et al 1994).
PFC nanoparticles have been developed to detect the 
sparse expression of the ανβ3 integrin on the neovascula-
ture (Anderson et al 2000) and to deliver anti-angiogenic 
therapy. This has been utilized in New Zealand white rabbits 
bearing Vx-2 tumors (1.0 cm) at 1.5T (Winter, Caruthers 
et al 2003). MRI signal 2 h post injection of ανβ3-targeted 
nanoparticles revealed signal enhancement of 126% pre-
dominantly in an asymmetrical distribution along the tumor 
border. These results paralleled the immunohistochemical 
staining results. Moreover, in vivo competitive blocking 
with ανβ3 targeted non-paramagnetic nanoparticles resulted 
in decreased signal enhancement to a level attributable to 
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Figure 5 (a) Representative spectrum taken at 4.7 T of crown ether emulsion 
(~90 ppm) and trichloroﬂ  uormethane (0 ppm) used as a reference. (b) The calibra-
tion curve for crown ether emulsion has a slope of 28.06 with an r2 of 0.9968. (c) 
The calculated number of bound nanoparticles (mean ± standard error, n = 3) as 
calculated from 19F spectroscopy versus the mass of total gadolinium (Gd3+) in the 
sample as determined by neutron activation analysis show excellent agreement as 
independent measures of ﬁ  brin-targeted nanoparticles binding to clots. The linear 
regression line has an r2 of 0.9997. Copyright © 2004. Reprinted with permission 
from Morawski AM, Winter PM, et al. 2004. Targeted nanoparticles for quantitative 
imaging of sparse molecular epitopes with MRI. Magnetic Resonance in Medicine, 
51:480–6.International Journal of Nanomedicine 2007:2(4) 522
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local extravasation. In an analogous study, athymic nude mice 
bearing human melanoma tumors (C32, ATCC; ~33mm3) 
were injected with ανβ3 targeted PFC nanoparticles and 
imaged at 2 h (Schmieder, Winter et al. 2005). MR enhance-
ment was apparent within 0.5 h and increased by 173% at 2 h 
(see Figure 7). Again, MR imaging results were corroborated 
with histological results. In both studies, in vivo competitive 
blocking with ανβ3 targeted non-paramagnetic nanoparticles 
inhibited the evolution of the targeted signal. These ﬁ  ndings 
speak to the high speciﬁ  city achievable with ανβ3 targeted 
nanoparticles.
Angiogenesis also plays a crucial and early role in the 
pathogenesis of atherosclerosis and the inhibition of angiogen-
esis has been shown to decrease plaque progression (Moulton 
et al 1999, 2003). Unfortunately, detection of atherosclerosis 
generally does not occur until late stages of the disease when 
a clinical event is caused by a plaque rupture. Conventional 
noninvasive imaging techniques are not sensitive or speciﬁ  c 
enough to detect the sparse biomarkers associated with 
early atherosclerosis. However, ανβ3-targeted paramagnetic 
nanoparticles have been demonstrated to spatially localize 
and quantify neovascularization associated with early ath-
erosclerosis in hyperlipidemic New Zealand White rabbits 
(see Figure 8) (Winter, Morawski et al 2003).
In addition to angiogenesis, ανβ3 has an important role in 
the development of restenosis following balloon injury from 
angioplasty. It is expressed following vascular injury and 
facilitates smooth muscle migration and proliferation, cell 
adhesion to the extracellular matrix as well as induction of 
extracellular metalloproteinase expression. Multiple animal 
studies have shown that IV administration of ανβ3 antagonism 
following balloon angioplasty results in decreased neointimal 
growth and lumen stenosis (Srivatsa et al 1997; Bishop et al 
2001). We have developed a high avidity ανβ3 integrin speciﬁ  c 
nanoparticle that can target ανβ3 integrin exposed on smooth 
muscle cells by arterial overstretch injury and provide new 
prognostic data relating the extent and severity of balloon 
injury as well as facilitate the delivery of therapeutic agents 
from within the damaged arterial wall (Cyrus et al 2003). 
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Figure 6 (a) Optical image of a 5-mm cross-section of a human carotid endarterectomy sample. This section showed moderate luminal narrowing as well as several 
atherosclerotic lesions. (b) A 19F projection image acquired at 4.7 T through the entire carotid artery sample shows high signal along the lumen due to nanoparticles bound 
to ﬁ  brin. (c) Concentration map of bound nanoparticles in the carotid sample. Copyright © 2004. Reprinted with permission from Morawski AM, Winter PM, et al. 2004. 
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magnetic Resonance in Medicine, 51:480–6. 
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Figure 7 (A) T1-weighted MR image (axial view) of an athymic nude mouse before 
injection of paramagnetic ανβ3-targeted nanoparticles. Arrow indicates a C32 
tumor that is difﬁ  cult to detect (“Ref” = Gd3+ DTPA in 10 cc syringe). (B) Enlarged 
section of an MR image showing T1-weighted signal enhancement of angiogenic 
vasculature of early tumors over 2 h as detected by ανβ3-targeted nanoparticles. 
Copyright © 2005. Reprinted with permission from Schmieder AH, Winter PM, 
et al. 2005. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-
targeted paramagnetic nanoparticles. Magnetic Resonance in Medicine, 53:621–7.International Journal of Nanomedicine 2007:2(4) 523
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Similar to ανβ3, collagen III is omni-present within the vascular 
wall and accessible immediately after balloon injury for tar-
geted delivery of therapeutic paramagnetic nanoparticles. We 
have covalently coupled a monoclonal Fab fragment speciﬁ  c 
for collagen III to target nanoparticles into carotid extracellular 
matrix following balloon overstretch injury in pigs, analogous 
to the studies previously described for ανβ3-targeted paramag-
netic nanoparticles (Cyrus et al 2003).
Contact facilitated drug delivery
Besides detecting sparse epitopes for non-invasive imaging, 
PFC nanoparticles are capable of speciﬁ  cally and locally deliv-
ering drugs and other therapeutic agents through a novel process 
known as contact facilitated drug delivery (Lanza et al 2004). 
Direct transfer of lipids and drugs from the outer surfactant 
layer to the cell membrane of the targeted cell is usually a slow 
and inefﬁ  cient process. Through ligand directed targeting, this 
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Figure 8 In vivo spin-echo image reformatted to display long axis of aorta from renal arteries to diaphragm of a cholesterol-fed rabbit (top) and at single transverse level 
(bottom) before (Pre) and after (Post) treatment, after semi-automated segmentation (Segmented, grayish ring), and with color-coded signal enhancement (Enhancement) 
above baseline (in percent). Copyright © 2003. Reprinted with permission from Winter PM, Morawski AM, et al. 2003. Molecular imaging of angiogenesis in early-stage 
atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation, 108:2270–4.
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Figure 9 Schematic representation illustrating contact-facilitated drug delivery. Phospholipids and drug within the nanoparticles surfactant exchange with lipids of the target 
membrane through a convection process, rather than diffusion, as is common among other targeted systems. Copyright © 2004. Reprinted with permission from Lanza GM, 
Winter PM, et al. 2004. Magnetic resonance molecular imaging with nanoparticles. Journal of Nuclear Cardiology, 11:733–43.International Journal of Nanomedicine 2007:2(4) 524
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process is accelerated by minimizing the separation of the lipids 
surfaces and increasing the frequency and duration of the lipid 
surface interactions (see Figures 9 and 10). Spatial localization 
(via high resolution 1H MR imaging) and quantiﬁ  cation of the 
nanoparticles (via 19F spectroscopy) permits the local therapeu-
tic concentrations to be estimated. Thus, PFC nanoparticles can 
be used for detection, therapy and treatment monitoring.
As an example, in vitro vascular smooth muscle cells were 
treated with tissue-factor targeted PFC nanoparticles containing 
0, 0.2, or 2.0 mole % doxorubicin or paclitaxel or an equivalent 
amount of drug in buffer solution alone (Lanza, Yu et al 2002). 
With only targeting for 30 minutes, proliferation measured 
at 72 hours was inhibited. High resolution MR imaging with 
4.7T revealed the image intensity of the targeted VSCM’s was 
2-fold higher as compared with nontargeted cells. In addition, 
the ﬂ  uorine signal amplitude at 0.47T was linearly correlated to 
the perﬂ  uorocarbon concentrations, which by direct inference 
could be related to nanoparticles number.
Conclusion
Ligand-directed liquid PFC nanoparticles are an extremely 
versatile imaging platform that permit noninvasive assess-
ment of clinically important sparce biomarkers, such as 
integrins in angiogenesis as well as high density epitopes, 
such as ﬁ  brin. The unique properties of targeted nanopar-
ticles present the opportunity to diagnose, deliver therapy 
Figure 10 In vitro targeting of FITC-labeled nanoparticles (white arrows) targeted to aνb3-integrin expressed by C-32 melanoma cells, which illustrate the delivery of 
FITC-labeled surfactant lipids into target cell membranes (yellow arrows). Scale bar = 2 microns. Copyright © 2004. Reprinted with permission from Lanza GM, Winter PM, 
et al. 2004. Magnetic resonance molecular imaging with nanoparticles. Journal of Nuclear Cardiology, 11:733–43.International Journal of Nanomedicine 2007:2(4) 525
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and predict therapeutic response with a single platform. 
Furthermore, they allow image based serial monitoring. 
Their impact in the ﬁ  elds of cardiology and oncology are 
predicted to be profound.
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